Because of these shared immune response genes, changes in the microbiome, and other environmental factors, the host immune response to EBV and other herpes viruses may be evolving unpredictably with the host immune response (Figure 1).
Dreyfus, "Gene sharing between Epstein-Barr virus and human immune response genes," Immunologic Research, 2016, Epub ahead of print.
The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).